We have identi®ed parameters which de®ne a causal role of HPV16 in head and neck cancer. Twenty-eight tumours which were typed positive for HPV16 DNA, were comprehensively analysed for expression of the viral oncogenes E6 and E7, the status of the p53 gene, and the protein status of pRb and p16
Introduction
A hall mark of squamous cell carcinomas of the head and neck (HNSCC) is an extensive heterogeneity at the histological, biological and clinical level. This heterogeneity makes it dicult to assess the malignancy of these tumours and to predict the outcome of tumour treatments such as radio-and/or chemotherapy. In order to overcome these diculties, it will be crucial to ®nd molecular markers de®ning certain genotypes and phenotypes and representing tumour subgroups with more homogeneous behaviour. Tumours associated with oncogenic human papillomaviruses (HPV) may represent such a subgroup in HNSCC. Evidence has accumulated that some of the oncogenic HPV types are associated with a subset of head and neck cancers, since HPV DNA was found to be present in HNSCC with various morphology and from various sites (oropharynx, oral cavity, larynx, hypopharynx, nasopharynx), with HPV16 DNA strongly predominating over HPV18, 33, and further types (de Villiers et al., 1985; Maitland et al., 1987; Yeudall and Campo, 1991; Rassekh et al., 1998; for review, zur Hausen, 1996) . In further studies, a rather frequent coexistence of HPV DNA and p53 mutations was found, and again all sites and histological grades were involved (Barten et al., 1995; Chiba et al., 1996; Scholes et al., 1997; He et al., 1997) . This is in strong contrast to the situation in cervical and other anogenital cancers which show an almost complete inverse correlation between HPV and p53 mutations and which share a conspicious undierentiated (basaloid) morpholgy (Schener et al., 1991; Fujita et al., 1992; Crook et al., 1992; Milde-Langosch et al., 1995; zur Hausen, 1996) .
A strong indicator of a causal relationship between HPV and HNSCC was identi®ed when the expression of the retinoblastoma susceptibility protein pRb was analysed. pRb is the major cellular target protein of the E7 oncoprotein of the high risk HPV types (Dyson et al., 1989; Hoppe-Seyler and Butz, 1994) . Reduced or absent pRb expression was found to be signi®cantly associated with the presence of HPV DNA (Andl et al., 1998; Wilczynksi et al., 1998) . The cell cycle components Cyclin D1 and p16
INK4a which are regulated by pRb, were also aected with Cyclin D1 also showing reduced expression and p16
INK4a being overexpressed in these tumours. In further support of a causal involvement of HPV, the pRb-defective phenotype of these HPVpositive tumours was also associated with the absence of p53 mutations (Andl et al., 1998) . Most of these tumours occurred in tonsils, were of poorly or undierentiated histology, and were metastatic at the time of diagnosis (Andl et al., 1998; Wilcznski et al., 1998) .
Expression of the viral oncogenes E6 and E7 may also represent an indicator of a causal relationship between HPV and HNSCC, in analogy to the situation in cervical cancer (von Knebel-Doeberitz et al., 1988) . In HNSCC, E6/E7 expression was consistently found only in studies focusing on HPV DNA-positive tonsillar carcinomas (Snijders et al., 1992; Wilczynksi et al., 1998) .
Integration of the viral genome into the tumour cell genome is a further indicator of a causal involvement of HPV in tumorigenesis, since HPV DNA integration in cervical cancer usually results in the disruption of the E1 and E2 ORFs the products of which are repressors of E6/E7 transcription (Schwarz et al., 1985) . In HNSCC, the integration state of HPV has been analysed only in some single cases (Kahn et al., 1994; Steenbergen et al., 1995) .
These considerations have prompted us to comprehensively examine the parameters indicative of a causal role of oncogenic HPV16 in head and neck carcinogenesis. We focused on HPV16 which is by far the most frequently detected HPV type in HNSCC. We have ®rst typed an arbitrarily selected tumour cohort for the presence of HPV16 DNA. These HPV16 DNA-positive tumours were then characterized in detail regarding E6/E7 oncogene expression by RT ± PCR, expression of pRb and p16
INK4a by immunohistochemistry and the status of the p53 gene by PCR-based cycle sequencing. Further, we have analysed the status of the E6 gene of HPV16 by genomic PCR and cycle sequencing. Finally, we have searched for viral-cellular fusion transcripts indicating integrated HPV DNA.
Results

HPV detection and typing
Eighty-eight arbitrarily selected tumours from all head and neck sites were subjected to HPV detection and typing. Twenty-eight tumours were typed positive for HPV16 using established procedures (see Materials and methods). Twelve of these 28 tumours were derived from the oropharynx (eight tonsillar tumours), ®ve were from the hypopharynx, four from the larynx, three from the oral cavity, one from the nasopharynx and three from minor sites. These 28 HPV16 DNApositive tumours were further examined.
p53 mutational analysis
All 28 tumours were subjected to genomic sequencing of the exons 4 to 9 of the p53 gene. Thirteen tumours revealed mutations, as listed in Table 1 . All mutations found were present in the conserved core domain (eight in exon 5, one in exon 6, three in exon 7 and one in exon 8). One mutation was a three nucleotide duplication in exon 8, whereas all other mutations were missense mutations. Thus, we observed coexistence of HPV16 DNA and p53 mutations.
E6/E7 expression
We asked whether E6/E7 expression could be detected in all HPV16 DNA-positive cases, or whether E6/E7 expression would de®ne a distinct subgroup of these HPV16 DNA-positive tumours. Following reverse transcription of total RNA extracted from tumours, both E6 and E7 were ampli®ed in a ®rst PCR reaction and the products analysed by agarose gel electrophoresis. In the negative cases, the E7 gene was ampli®ed further in a second nested PCR reaction. Some examples are shown in Figure 1 . All negative reactions as well as some positive reactions were repeated by random priming RT ± PCR. This analysis fully con®rmed the former results (data not shown). Expression of E6/E7 could only be found in 12 of the 28 HPV DNA-positive carcinomas. Remarkably, nine of the 12 tumours expressing the E6 and E7 oncogenes were located in the oropharynx.
Comparison of p53 status and E6/E7 expression
This comparison was performed to determine a possible relationship between p53 and HPV16 status. As shown in Table 2 , E6/E7 expression showed a completely dierent relationship to the mutational status of p53 than did HPV16 DNA. With one exception, E6/E7 expression occurred only in tumours INK4a staining are presented in Figure 2 . As shown in Table 3 , most tumours (10 of 12) with E6/E7 expression revealed strongly reduced pRb protein staining. In most of these (eight of 10), the p16
INK4a protein was overexpressed. In contrast, most tumours (10 of 12) without E6/E7 expression revealed normal pRb staining, and most (10 of 12) also revealed very low levels of p16 INK4a . Thus, E6/E7 expression correlated strongly with a perturbed pRb/p16
INK4a pathway.
Mutational analysis of the E6 gene
We next asked whether in the HPV16 DNA-positive tumours without E6/E7 expression, mutational events in the E6 gene were responsible for the lack of expression. (Figure 3 ). Very surprisingly, E6 PCR products could be ampli®ed only in two tumours without E6/E7 expression (tumour numbers 13 and 17, Table 3 ), whereas in all eight control cases with E6/E7 expression and in tumour number 24, E6 PCR products could be detected, as expected. Thus, in 11 of the 13 tumours lacking E6/E7 expression, the E6 gene seems to be deleted. Sequencing of the E6 gene of tumours numbers 24, 13 and 17 did not reveal any mutations. Tumours number 13 and 24 showed the established prototype E6 gene sequence (Seedorf et al., 1985) . Tumour number 17 showed the same variant sequence (nucleotide position 350, T-G transversion) which we also found in the SiHa DNA, in agreement with previous results (el Awady et al., 1987) .
Analysis of viral-cellular fusion transcripts
Viral-cellular fusion transcripts obtained after RT ± PCR ampli®cation are regarded as indicators of HPV DNA integration and, in addition, can be used to identify the chromosomal integration site. In the tumours with E6/ E7 expression, we have analysed integration using a modi®ed APOT assay (Klaes et al., 1999) . Figure 4 shows the results of RT ± PCR ampli®cation (top panel) followed by Southern blot hybridization with an E7 probe (bottom panel) of tumour numbers 6, 8, 3, 9, 7, 24 and 28. The products which hybridized to the E7 probe were cloned and sequenced. Viral-cellular fusion transcripts were identi®ed in tumours number 3 and 8. In the other tumours, only viral sequences were present.
In the cDNA of tumour number 3, the viral sequences were spliced at the E1 splice donor site at nucleotide position 880 to a 150 bp cellular sequence. In tumour number 8, two viral-cellular fusion products were found. In both, the junction between the viral and the 96 bp cellular sequences was located in the E1 gene at position 950, untypical for a E1 splice donor site. The two products diered at their 5' ends, one of them showing duplication of the E6 and E7 region ( Figure  5 ). The duplication event involved the E1 splice donor site at nucleotide position 880 which was fused to nucleotide position 409 in the E6 gene.
In order to analyse whether the transition between the viral and cellular sequences at position 950 in E1 was generated by an untypical splicing event or represented the direct viral-cellular junction, we compared genomic DNA and cDNA by half-nested PCR analysis, using primers located in the cellular sequence and in the E7 and Figure 3 Disruption of the E6 gene as revealed by genomic PCR of the E6 ORF. The primers used for half-nested PCR are given in Materials and methods. The E6 gene was not ampli®able in tumour numbers 4 and 10, whereas intact E6 was ampli®ed from SiHa DNA (PC) and tumour numbers 13, 17, 5 and 28 BlastN analysis of the co-transcribed cellular sequences revealed that they are located in chromosome 5 (tumour number 3) and chromosome 6 (tumour number 8), respectively ( Figure 5 ).
Discussion
In this study we have comprehensively examined the essential parameters which de®ne a causal role of oncogenic HPV in head and neck carcinogenesis, focusing on HPV16. Twenty-eight tumours found to be positive for HPV16 DNA which did not represent a distinct entity in terms of histological appearance and anatomical localization, were analysed for the presence of p53 mutations, expression of E6/E7 and viral DNA integration. In most of these cases, expression of pRb (C) show the co-transcribed cellular sequences of chromosomes 6 in tumour 8 and chromosome 5 in tumour 3, respectively. The co-transcribed chromosome-6-sequence is located within the assembled sequence NT_023412 which comprises nearly 6 Mb. Genes located in this genomic region encode the bone morphogenetic protein 6 (BMP6), the ras-responsive element binding protein 1 (RREB1), the eukaryotic translation elongation factor 1 epsilon 1 (EEF1E1), and the RP105-associated protein MD-1. The co-transcribed chromosome-5-sequence could be localized within the assembled sequence with the accession number NT_023174 (251 kb). The cellular sequence identi®ed is part of an expressed gene (Harrington et al., 2001 ) Figure 4 Analysis of HPV16 DNA integration. RT ± PCR ampli®cation (top panel) was performed as described in Materials and methods. The agarose gel was blotted to a nylon membrane and hybridized with an E7 probe (bottom panel). Only those products which had hybridized (arrow heads indicate approximate sizes of fragments) were excised from a second gel, cloned and sequenced and p16
INK4a and the presence of the E6 gene was also analysed.
Only 12 of the 28 HPV16 DNA-positive tumours revealed E6/E7 expression by RT ± PCR. Remarkably, the tumours expressing E6/E7 appeared as a more homogeneous group: nine were located in the oropharynx, they were of advanced TNM stage, and they shared a poorly-dierentiated morphology, in agreement with our previous study (Andl et al., 1998) . This low proportion of E6/E7 expression which is in agreement with a recent study (van Houten et al., 2001) , is in clear contrast to uterine cervix, where it is believed that most if not all HPV DNA-positive cancers express E6/E7 (von Knebel-Doeberitz et al., 1988) . Together with these previous studies (Snijders et al., 1992; Wilczynksi et al., 1998; van Houten et al., 2001 ), our results demonstrate that E6/E7 expression in HNSCC is predominantly found in the tumour site oropharynx, speci®cally the tonsils.
The comparison between the E6/E7 expression status and the p53 status showed that with only one exception, the tumours expressing E6/E7 contained wild-type p53 (exons 4 to 9). In contrast, most tumours not expressing E6/E7 contained a mutated p53 gene. Thus, viral E6/E7 expression is very strongly correlated with a wild-type p53 gene, but this relationship is not mutually exclusive as recently stated (van Houten et al., 2001 ). The exceptional case showed true coexistence of mutated p53 and E6/E7 expression at least in a fraction of tumour cells, since the viral E6 gene was found to be intact and of the well-known prototype, the p53 mutation was homozygous, and the pRb level was reduced throughout the tumour areas analysed. Whether protein ± protein interaction between the mutated p53 and E6 in this exceptional case was disturbed as has been shown in transfection assays (Gardiol and Banks, 1998) is unclear.
The analysis of the pRb status by immunohistochemistry further strengthened the functional relationship between HPV16 E6/E7 expression and head and neck carcinogenesis. The correlation between E7 expression and reduced pRb is very strong and further supported by overexpression of p16
INK4a in most cases, whereas the mere presence of HPV DNA is only weakly correlated with reduced pRb (see Table 3 ). Thus, a perturbed pRb cell cycle control is a very strong indicator of a causal involvement of HPV in HNSCC.
Genomic E6 PCR and sequencing yielded very surprising results: While the E6 gene was intact in all tumours with E6/E7 expression, it was disrupted in most tumours without E6/E7 expression. This novel ®nding convincingly explains why these tumours did not express E6, and in those cases in which the pRb level appeared normal, also did not express E7 (Table 3) . It must be stressed, however, that in a few tumours harbouring a mutated p53, the E6 gene could be detected (Table 3) . In these cases, the lack of E6/E7 expression (based on the observation of a normal pRb level) might be due to alterations in transcriptional control.
Hence, if an intact E6 gene is found by genomic PCR and/or sequencing, expression of E6/E7 strongly implies a causal involvement of the virus in tumour development and progression. In contrast, ®nding a disrupted E6 gene in the viral genome strongly argues against a causal role of HPV in the carcinogenic process irrespective of whether the virus genome has persisted in an episomal or integrated state. These results contradict recent argumentation (Gillison et al., 2000) . These authors have suggested that p53 mutations might prevent interaction with E6 but HPV might still be causally involved due to the action of the E7 protein. However, our results show that most such tumours will not express E6/E7 because the E6 gene is disrupted. The genomic E6 status appears to be of high diagnostic value.
In two of the 12 tumours expressing E6/E7, we have identi®ed transcripts consisting of viral and cellular sequences ( Figure 5 ). Both of these cases showed interesting features. Tumour number 8 revealed a duplication of the E6/E7 region which could lead to increased oncogene dosis, and a direct viral-cellular junction on chromosome 6. Some genes potentially of interest are located within an area of about 6 Mb adjacent to the integration site, e.g. EEF1E1, BMP6 and MD-1. Whether the regulation of expression of these genes is aected in this tumour by the viral integration is unclear. Interestingly, the cellular sequence identi®ed in tumour number 3 is part of an expressed gene (Harrington et al., 2001) . It is very likely that the integration event in this case has disrupted a gene. Altogether, integration of HPV16 with an intact E6/E7 region resulting in viral-cellular fusion transcripts, occurs less frequently in HNSCC than in cervical cancer. It should be noted that integration of HPV16 in cervical cancer also occurss at markedly lower frequency as compared to integration of HPV18 (Matsukura et al., 1989; Cullen et al., 1991; Berumen et al., 1994) .
In conclusion, we have identi®ed parameters which very clearly indicate that HPV16 is causally associated only with a subset of HPV DNA-positive head and neck cancers. Expression of E6/E7 rather than the presence of HPV DNA is an important but not the sole indicator. Equally important is the functional inactivation of pRb cell cycle control. We have found a novel and important indicator of a causal relationship, i.e. the presence of an intact E6 gene. We propose that future HPV detection in head and neck cancer should include the analysis of the E6 gene. In contrast, the presence of a p53 mutation is a very strong but not unequivocal indicator against a causal role of HPV in HNSCC.
Materials and methods
Patients and biopsy material
Tumour biopsies were divided into two parts: One part was snap-frozen in precooled isopentane/liquid nitrogen immediately after surgery and stored at 7808C. The second part was formalin ®xed and paran-embedded. Histopathological assessment was performed on paran sections.
HPV detection and typing
For HPV detection, genomic DNA (250 ng) of the tumour samples was subjected to PCR using the MY09 and MY11 degenerate consensus primers, followed by ®lter hybridization of the blotted PCR products with a 32 P-labelled consensus L1 probe (Resnick et al., 1990) . For HPV typing, multiplex PCR and Southern blot hybridization was performed as described (van den Brule et al., 1989) . In addition, PCR and hybridization using only the HPV16-speci®c anticontamination primers and hybridization probe, respectively, were performed. Alternatively, the ®lters with the consensus PCR products were hybridized with the HPV16-speci®c L1 oligonucleotide 5'-GTCATTATGTGCTGCCATATCTACT-TCAGA-3' (Jacobs et al., 1995) .
PCR-cycle sequencing of p53 exons 4 ± 9
Tumour-DNA was prepared from microdissected tissues using the Qiamp tissue kit from QIAGEN (Hilden, Germany). After initial ampli®cation of exons 4 ± 9 with primers E4/C4 and E9//C1, exons 4 ± 6 (primers E4/C3, 2997) and 7 ± 9 (primers E7-C4, E9//C1) were further ampli®ed as described previously . Cycle-sequencing was performed using the BigDyeDeoxy Terminator Cycle Sequencing kit (Applied Biosystems, Weiterstadt, Germany) and the sequences were analysed on the ABI-Prism 310 Genetic Analyser. Primer sequences: E4/C4, 5'-GCTGAG-GACCTGGTCCTCT-3'; E9//C1, 5'-CGGCATTTTGAGT-GTTAGAC-3'; E4/C3,5'-GACTGCTCTTTTCACCCATC-3'; 2997, 5'C-CACTGACAACCACCCTTAAC-3'; E7/C4, 5'-CTGGCCTCATCTTGGGCCTG-3'.
RNA extraction and reverse transcription (RT)
Total cellular RNA was isolated from microdissected tissues using the RNeasy Total RNA Puri®cation Kit (QIAGEN, Hilden, Germany). RT was performed using an oligo-dTprimer d(T) 17 coupled with an adaptor sequence (5'-GAGACTCGAGAATTCCATGGT- (T) 17 N) following the manufacturers instructions (SuperScript kit, Life technologies, Karlsruhe, Germany). For quality control, all cDNAs were probed with primers for the human b-actin gene (Nakajima-lijima et al., 1985) .
